Hessels, J.; Kroon, S.; Boerman, S.; Nelissen, R.C.; Grutters, J.C.; Snijder, R.J.; Lebrin, F.; Post, M.C.; Mummery, C.L.; Mager, J.-J.
Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study. J. Clin. Med. 2022, 11, 5280.
https://doi.org/10.3390/jcm11185280
AMA Style
Hessels J, Kroon S, Boerman S, Nelissen RC, Grutters JC, Snijder RJ, Lebrin F, Post MC, Mummery CL, Mager J-J.
Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study. Journal of Clinical Medicine. 2022; 11(18):5280.
https://doi.org/10.3390/jcm11185280
Chicago/Turabian Style
Hessels, Josefien, Steven Kroon, Sanne Boerman, Rik C. Nelissen, Jan C. Grutters, Repke J. Snijder, Franck Lebrin, Marco C. Post, Christine L. Mummery, and Johannes-Jurgen Mager.
2022. "Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study" Journal of Clinical Medicine 11, no. 18: 5280.
https://doi.org/10.3390/jcm11185280
APA Style
Hessels, J., Kroon, S., Boerman, S., Nelissen, R. C., Grutters, J. C., Snijder, R. J., Lebrin, F., Post, M. C., Mummery, C. L., & Mager, J.-J.
(2022). Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study. Journal of Clinical Medicine, 11(18), 5280.
https://doi.org/10.3390/jcm11185280